

Pauline McCormack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2477147/publications.pdf>

Version: 2024-02-01

11
papers

365
citations

1039880

9
h-index

1372474

10
g-index

12
all docs

12
docs citations

12
times ranked

661
citing authors

#	ARTICLE	IF	CITATIONS
1	Delivering genomic medicine in the United Kingdom National Health Service: a systematic review and narrative synthesis. <i>Genetics in Medicine</i> , 2019, 21, 2667-2675.	1.1	17
2	“You should at least ask”™. The expectations, hopes and fears of rare disease patients on large-scale data and biomaterial sharing for genomics research. <i>European Journal of Human Genetics</i> , 2016, 24, 1403-1408.	1.4	70
3	Improving the informed consent process in international collaborative rare disease research: effective consent for effective research. <i>European Journal of Human Genetics</i> , 2016, 24, 1248-1254.	1.4	47
4	New Recommendation on Biological Materials Could Hamper Muscular Dystrophy Research. <i>PLOS Currents</i> , 2016, 8, .	1.4	0
5	International Charter of principles for sharing bio-specimens and data. <i>European Journal of Human Genetics</i> , 2015, 23, 721-728.	1.4	112
6	Precaution, governance and the failure of medical implants: the ASR(TM) hip in the UK. <i>Life Sciences, Society and Policy</i> , 2014, 10, 19.	3.1	24
7	Setting up strategies: patient inclusion in biobank and genomics research in Europe. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, P2.	1.2	8
8	Therapeutic Misconception: Hope, Trust and Misconception in Paediatric Research. <i>Health Care Analysis</i> , 2014, 22, 3-21.	1.4	24
9	DISPUTING THE ETHICS OF RESEARCH: THE CHALLENGE FROM BIOETHICS AND PATIENT ACTIVISM TO THE INTERPRETATION OF THE DECLARATION OF HELSINKI IN CLINICAL TRIALS. <i>Bioethics</i> , 2013, 27, 243-250.	0.7	29
10	Guidance in Social and Ethical Issues Related to Clinical, Diagnostic Care and Novel Therapies for Hereditary Neuromuscular Rare Diseases: “Translating” the Translational. <i>PLOS Currents</i> , 2013, 5, .	1.4	15
11	The risks of therapeutic misconception and individual patient (n=1) “trials” in rare diseases such as Duchenne dystrophy. <i>Neuromuscular Disorders</i> , 2011, 21, 13-15.	0.3	19